JUNS 10-Q filed 2026-11-16 | Key takeaways
JUNS filed its 10-Q; the most relevant disclosure change is added Business combinations: Company entered a definitive Strategic Asset License Agreement with PharmAla Biotech Holdings Inc. on July 20, 2026 for exclusive U.S. rights to ALA-002, a proprietary MDMA formulation. Upfront consideration of $3,333,333 comprised of $1,500,000 cash and $1,83.
Key takeaways
Going concern: management concluded that substantial doubt exists about the company's ability to continue as a going concern, citing recurring losses, negative cash flows and dependence on financing; net cash used in operating activities was $6,447,385 for the nine months ended September 30, 2026.
PharmAla ALA-002 license (announced July 20, 2026, closed July 21, 2026): upfront consideration of $3,333,333 in cash and stock, development milestones up to $23,333,333, commercialization milestones up to $73,333,333 and a 3% royalty on net sales; 132,867 shares were issued on August 20, 2026 with a 181,529-share remaining issuance obligation, and the stated rationale is to expand the pharmaceutical pipeline with a proprietary MDMA-based drug candidate...
Nasdaq listing risk: the company failed to regain compliance with the market value of listed securities requirement; the Panel granted an extension to November 16, 2026 and the company has requested a further extension to December 11, 2026.
Convertible notes amendment (November 16, 2026): $225,688 of outstanding principal with YA II PN, Ltd. (Yorkville) was extended to December 16, 2026 at 8% interest (18% upon default), with a $21,794 extension fee and a $112.50 per share conversion price, as additional time for financing activities.
Capital raises: two registered direct offerings in 2026 generated $4,000,000 of gross proceeds (May at $21.00 per share, August at $6.50 per share) for 402,930 shares, with $280,000 of placement agent fees, and proceeds directed to pay down convertible notes and fund operations; no registered shares remained available under the SEPA as of November 16, 2026.
Related-party support: executive officers and directors forgave $875,315 of accrued compensation in August 2026.
Litigation: three class action lawsuits were filed in 2026 alleging IPO disclosure failures related to social media promotion schemes, two of which seek dismissal.
Key metrics
Disclosure changes
- Business combinations
Company entered a definitive Strategic Asset License Agreement with PharmAla Biotech Holdings Inc. on July 20, 2026 for exclusive U.S. rights to ALA-002, a proprietary MDMA formulation. Upfront consideration of $3,333,333 comprised of $1,500,000 cash and $1,833,333 in common stock. Development milestones up to $23,333,333 and commercialization milestones up to $73,333,333. 3% royalty on net sales. The company recorded $3,333,333 as acquired in-process R&D expense.
Major strategic transaction expanding company's pharmaceutical pipeline to include psychedelic-based CNS drug candidate; significant milestone payment obligations; cash or share settlement risk if shareholder approval not obtained - Liquidity and capital resources
Cash of $300,623 as of September 30, 2026; approximately $110 thousand as of November 16, 2026. No registered shares available for resale under SEPA. Company engaged Tungsten Advisors as strategic advisor. Management concluded substantial doubt about ability to continue as going concern. Company entered second omnibus amendment to extend convertible note maturity to December 16, 2026.
Severely constrained liquidity; no SEPA capacity remaining; going concern doubt; potential delisting from Nasdaq; company exploring strategic alternatives - Related-party transactions
Executive officers and directors forgave $875,315 of accrued and unpaid compensation on August 26, 2026 without cash, equity or other consideration. Recorded as capital contribution in additional paid-in capital.
Related parties providing debt relief to preserve company cash; non-cash equity transaction with no impact on net loss or cash flows - Legal proceedings
Company is defendant in three class action lawsuits filed in 2026 in New York State court alleging IPO disclosure failures regarding social media promotion schemes. Plaintiffs seeking unspecified damages. In October 2026, plaintiffs in two lawsuits asked court to drop claims against company. Third lawsuit remains pending. No liability recorded.
Litigation exposure from IPO; potential liability if cases proceed; two cases potentially being dismissed - Nasdaq compliance
Company failed to regain compliance with market value of listed securities requirement ($35 million threshold). Panel granted extension to November 16, 2026. Company will not regain compliance within extension term. Company requested further extension to December 11, 2026. If Nasdaq declines, common stock will be delisted.
Risk of Nasdaq delisting; would adversely affect liquidity, ability to raise capital, and stock price - Stockholders' equity
1-for-75 reverse stock split effective August 6, 2026. Shares outstanding increased from 664,670 (June 30, 2026) to 1,318,521 (September 30, 2026) due to stock issuances including 132,867 shares under PharmAla license, 307,692 shares from registered direct offering, and shares issued for note payments. Stockholders' equity deficit of $1,162,002 at September 30, 2026.
Significant dilution from multiple equity issuances; reverse split did not prevent delisting risk; equity deficit increased
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow JUNS in real time
Get material earnings, filing, IR, and earnings-call alerts by email.